Try our Advanced Search for more refined results
November 17, 2017
IN RE: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation
View recent docket activity
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.
Coverage
-
January 25, 2018
Allergan, Restasis Buyers Can't Agree On MDL Venue
All parties involved in antitrust suits claiming Allergan Inc. delayed the launch of generic versions of its dry-eye medication Restasis — in part by transferring patents to a Native American tribe — agreed Thursday that the Judicial Panel on Multidistrict Litigation should consolidate the cases, but they differed on the venue when they pitched Texas, California and New York as options.
Parties
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
- Direct access to case information and documents.
- All significant new filings across U.S. federal district courts, updated hourly on business days.
- Full-text searches on all patent complaints in federal courts.
- No-fee downloads of the complaints and so much more!
TRY LAW360 FREE FOR SEVEN DAYS
Already a subscriber? Click here to login